title: MEK inhibitors beyond monotherapy: current and future development.
abstract: The development of MEK inhibitors has led to improved progression-free survival in patients with mutant BRAF(V600) cancers when used in combination with BRAF inhibitors. However, resistance to combination therapy remains an issue. This review summarizes our current understanding of the role of MEK in cancer cell proliferation and the mechanisms which lead to resistance in patients. Specific adverse events, which have been linked to the MEK inhibitor class, have been described. Future combinations of MEK inhibitors with other cancer therapy options, currently under investigation in clinical trials, are also discussed.
authors.affiliation: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 USA.
authors.forename: Ian E
authors.initials: IE
authors.lastname: Templeton
authors.affiliation: Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080 USA. Electronic address: musib.luna@gene.com.
authors.forename: Luna
authors.initials: L
authors.lastname: Musib
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D005544:Forecasting; D006801:Humans; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D009369:Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage*; D016032:Randomized Controlled Trials as Topic
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors